Royal Bank of Canada’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2K Sell
1,551
-5,217
-77% -$7.59K ﹤0.01% 6716
2025
Q4
$7K Sell
6,768
-715,667
-99% -$983K ﹤0.01% 6589
2025
Q3
$975K Sell
722,435
-52,039
-7% -$59.1K ﹤0.01% 4011
2025
Q2
$732K Buy
774,474
+771,315
+24,416% +$500K ﹤0.01% 4170
2025
Q1
$1K Sell
3,159
-6,752
-68% -$4.26K ﹤0.01% 6679
2024
Q4
$7K Sell
9,911
-1,488
-13% -$1.79K ﹤0.01% 6453
2024
Q3
$18K Buy
11,399
+561
+5% +$999 ﹤0.01% 6137
2024
Q2
$18K Buy
10,838
+8,670
+400% +$15.6K ﹤0.01% 6112
2024
Q1
$5K Sell
2,168
-26,917
-93% -$57.8K ﹤0.01% 6447
2023
Q4
$44K Buy
29,085
+15,307
+111% +$18.2K ﹤0.01% 6050
2023
Q3
$15K Buy
13,778
+5,871
+74% +$10.3K ﹤0.01% 6281
2023
Q2
$18K Buy
7,907
+3,247
+70% +$8.62K ﹤0.01% 6267
2023
Q1
$11K Sell
4,660
-7,960
-63% -$18.2K ﹤0.01% 6266
2022
Q4
$24K Buy
12,620
+11,585
+1,119% +$24.7K ﹤0.01% 6233
2022
Q3
$2K Buy
1,035
+115
+13% +$318 ﹤0.01% 7037
2022
Q2
$2K Sell
920
-3,891
-81% -$7.42K ﹤0.01% 6966
2022
Q1
$10K Sell
4,811
-8,975
-65% -$24.9K ﹤0.01% 6945
2021
Q4
$54K Buy
13,786
+7,109
+106% +$34.5K ﹤0.01% 6336
2021
Q3
$31K Buy
6,677
+1,492
+29% +$6.12K ﹤0.01% 6444
2021
Q2
$23K Buy
5,185
+533
+11% +$2.57K ﹤0.01% 6496
2021
Q1
$27K Buy
4,652
+3,440
+284% +$23.8K ﹤0.01% 6251
2020
Q4
$4K Sell
1,212
-443
-27% -$845 ﹤0.01% 6731
2020
Q3
$2K Buy
1,655
+363
+28% +$646 ﹤0.01% 6324
2020
Q2
$3K Sell
1,292
-2,301
-64% -$4.51K ﹤0.01% 6187
2020
Q1
$7K Buy
3,593
+2,998
+504% +$8.92K ﹤0.01% 5942
2019
Q4
$3K Sell
595
-183
-24% -$704 ﹤0.01% 6491
2019
Q3
$2K Buy
778
+39
+5% +$121 ﹤0.01% 6290
2019
Q2
$5K Sell
739
-20
-3% -$120 ﹤0.01% 6310
2019
Q1
$4K Buy
759
+450
+146% +$2.73K ﹤0.01% 6343
2018
Q4
$2K Sell
309
-896
-74% -$7.26K ﹤0.01% 6449
2018
Q3
$13K Buy
1,205
+735
+156% +$8.42K ﹤0.01% 5879
2018
Q2
$6K Sell
470
-716
-60% -$7.32K ﹤0.01% 5984
2018
Q1
$10K Buy
1,186
+526
+80% +$4.86K ﹤0.01% 5714
2017
Q4
$7K Sell
660
-4,095
-86% -$42.5K ﹤0.01% 5982
2017
Q3
$58K Buy
4,755
+4,398
+1,232% +$64.9K ﹤0.01% 5327
2017
Q2
$6K Sell
357
-1,240
-78% -$19.2K ﹤0.01% 5982
2017
Q1
$24K Buy
1,597
+118
+8% +$1.75K ﹤0.01% 5538
2016
Q4
$20K Sell
1,479
-16,207
-92% -$260K ﹤0.01% 5764
2016
Q3
$319K Sell
17,686
-7,488
-30% -$121K ﹤0.01% 4085
2016
Q2
$362K Sell
25,174
-6,712
-21% -$91K ﹤0.01% 3964
2016
Q1
$381K Buy
31,886
+31,101
+3,962% +$326K ﹤0.01% 3875
2015
Q4
$11K Sell
785
-1,608
-67% -$19.8K ﹤0.01% 5934
2015
Q3
$26K Sell
2,393
-854
-26% -$9.33K ﹤0.01% 5451
2015
Q2
$26K Buy
3,247
+1,661
+105% +$12.2K ﹤0.01% 5569
2015
Q1
$10K Buy
1,586
+435
+38% +$2.97K ﹤0.01% 5573
2014
Q4
$7K Buy
1,151
+17
+1% +$137 ﹤0.01% 5714
2014
Q3
$11K Buy
1,134
+333
+42% +$3.56K ﹤0.01% 5452
2014
Q2
$9K Buy
801
+107
+15% +$1.15K ﹤0.01% 5437
2014
Q1
$9K Sell
694
-505
-42% -$6.45K ﹤0.01% 5462
2013
Q4
$15K Sell
1,199
-675
-36% -$10.7K ﹤0.01% 5353
2013
Q3
$31K Buy
1,874
+1,781
+1,915% +$29.9K ﹤0.01% 5011
2013
Q2
$1K Buy
+93
New +$1.41K ﹤0.01% 5726

Other funds holding LXRX

Royal Bank of Canada's LXRX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Lexicon Pharmaceuticals (LXRX) stake by 77% in Q1 2026, selling an estimated $7.59K and leaving 1,551 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6716.

Royal Bank of Canada first reported a position in LXRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $975K in Q3 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Royal Bank of Canada held 1,551 shares of Lexicon Pharmaceuticals worth $2K as of Q1 2026.
  • Royal Bank of Canada sold 5,217 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $7.59K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6716 holding.
  • Royal Bank of Canada first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Lexicon Pharmaceuticals position peaked at $975K in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.